The idea is to pool resources to buy innovative medicines and reinforce their purchasing position in order to negotiate a better deal on the normally expensive drugs.
Last year, national drugs watchdog, Infarmed, approved around 50 new drugs, representing an extra financial stretch for the state in the region of two billion euros.
A further 20 next-generation medicines are expected to reach the national market this year.